Literature DB >> 8986737

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus.

M S Wyand1, K H Manson, A A Lackner, R C Desrosiers.   

Abstract

A major safety concern of using live-attenuated vaccine strategies against AIDS is the potential exposure of neonates or fetuses to vaccine virus from the mother. Here we report that high viral loads and disease were observed in only 2 of 18 neonatal monkeys infected with gene-deleted vaccine strains of simian immunodeficiency virus. Pathogenicity was restricted to neonates born to unvaccinated mothers, that is, lacking maternal immunity, and that received extremely high doses of vaccine virus orally. No in utero transmission of vaccine virus was observed in four neonates born to mothers vaccinated during the second trimester. Our results suggest that the live attenuated vaccine approach should remain a viable option for preventing HIV infection and disease in high-risk human populations.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8986737     DOI： 10.1038/nm0197-32

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  35 in total

1.  Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge.

Authors:  D L Sodora; K E Sheridan; P A Marx; R I Connor
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Authors:  J Benson; C Chougnet; M Robert-Guroff; D Montefiori; P Markham; G Shearer; R C Gallo; M Cranage; E Paoletti; K Limbach; D Venzon; J Tartaglia; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef.

Authors:  E Khatissian; V Monceaux; M C Cumont; M P Kieny; A M Aubertin; B Hurtrel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.

Authors:  E T Sawai; M S Hamza; M Ye; K E Shaw; P A Luciw
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques.

Authors:  I H Khan; E T Sawai; E Antonio; C J Weber; C P Mandell; P Montbriand; P A Luciw
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.

Authors:  M G Lewis; J Yalley-Ogunro; J J Greenhouse; T P Brennan; J B Jiang; T C VanCott; Y Lu; G A Eddy; D L Birx
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains.

Authors:  B Berkhout; K Verhoef; J L van Wamel; N K Back
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.